Axoltis Pharma raises €18 million to advance ALS drug
Biotech company Axoltis Pharma has raised €18 million to accelerate the development of an amyotrophic lateral sclerosis (ALS) drug candidate.
The closure of a Series A financing round will enable Axoltis to develop lead candidate NX210x, currently in Phase II clinical trials in patients with ALS.
The financing round was co-led by FIDAT Ventures and Cenitz with support from Agile Capital Market, an investment bank that supported the company by presenting Axoltis to key investors. Legacy investors, including Norfoalk, the Fonds Régional Avenir Industrie Auvergne Rhône-Alpes (Auvergne Rhône-Alpes Regional Industry Future Fund) also participated in the round.
Axoltis is currently conducting the Phase II ‘SEALS’ clinical trial, evaluating the efficacy and tolerability of NX210c in 82 patients with ALS. The trial also measures how the drug candidate helps repair the blood-brain barrier, which becomes damaged in many neurodegenerative disorders such as ALS, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.
“At a time when biotech funding remains particularly challenging, the success of this round demonstrates that investors believe in our strategy,” said Yann Godfrin, CEO of Axoltis Pharma.
“I wish to extend my warmest thanks to the historic investors and newcomers for their trust, support and enthusiasm, and the enlightening discussions we held over the course of their thorough due diligence during the last few months.”
Results from the Phase II ‘SEALS’ trial are expected in Q2 2026.
Bruno Quinney, Content Team, DDW
